Purpose Patients with glioblastoma usually have a very poor prognosis. Even with a combination of radiotherapy plus temozolomide, the median survival of these patients is only 14.6 months. New treatment approaches to this cancer are needed. Our purpose is to develop new cell surface-binding ligands for glioblastoma cells and use them as targeted imaging and therapeutic agents for this deadly disease. Methods One-bead one-compound combinatorial cyclic peptide libraries were screened with live human glioblastoma U-87MG cells. The binding affinity and targeting specificity of peptides identified were tested with in vitro experiments on cells and in vivo and ex vivo experiments on U-87MG xenograft mouse model. Results A cyclic peptide, LXY1, was identified and shown to be binding to the α3 integrin of U-87MG cells with moderately high affinity (K d =0.5±0.1 μM) and high specificity. Biotinylated LXY1, when complexed with streptavidin-Cy5.5 (SA-Cy5.5) conjugate, targeted both subcutaneous and orthotopic U-87MG xenograft implants in nude mice. The in vivo targeting specificity was further verified by strong inhibition of tumor uptake of LXY1-biotin-SA-Cy5.5 complex when intravenously injecting the animals with anti-α3 integrin antibody or excess unlabeled LXY1 prior to administrating the imaging probe. The smaller univalent LXY1-Cy5.5 conjugate (2,279 Da) was found to have a faster accumulation in the U-87MG tumor and shorter retention time compared with the larger tetravalent LXY1-biotin-SA-Cy5.5 complex (approximately 64 kDa). Conclusions Collectively, the data reveals that LXY1 has the potential to be developed into an effective imaging and therapeutic targeting agent for human glioblastoma.
phosphate-buffered saline resection followed by radiation and chemotherapy has been shown to only slightly increase patient survival [1] . There is a need for new approaches that can selectively target glioblastoma.
Integrins are expressed in most, if not all, cell types and have been implicated in a variety of biological processes including embryonic development, inflammation, thrombosis, tumor cell adhesion, metastasis, and adhesion-mediated drug resistance [2] . Integrins are transmembrane glycoprotein complexes of noncovalently linked α and β subunits. There are eight known β subunits that combine with 18 α subunits in a defined manner to create more than 24 unique αβ heterodimers [3] . It has been shown that brain tumor cells and proliferating tumor vasculature express high levels of the cell adhesion receptor αvβ3 and αvβ5 integrins in vitro and in vivo [4] . Cyclic RGDfK peptide, a well-known ligand against αvβ3 integrin, has been widely used as an optical and radioimaging agent for solid tumors including glioblastoma when conjugated with fluorescent dye or radionuclide, respectively [5] . Additionally, an extensive study on integrin expression patterns in normal and tumor tissues of the brain indicated that integrin α3β1 is the major integrin isotype expressed in glioma cells [6] .
Through screening random one-bead one-compound (OBOC) cyclic peptide libraries, we previously identified a cyclic peptide motif, cDGXGXXc, to bind preferentially to ovarian cancer with high specificity against α3 integrin [7] . We then synthesized and screened a cXGXGXXcfocused library against U-87MG human glioblastoma cells and identified a new cyclic peptide cdGLGBNc (named LXY1), wherein B stands for L-hydroxyproline, as an excellent ligand against U-87MG cells. In this paper, we demonstrate that LXY1 binds to α3 integrin on brain tumors with high specificity and moderately high affinity utilizing in vitro binding experiments, as well as in vivo and ex vivo near-infrared fluorescent (NIRF) optical imaging studies in xenograft models. The biodistribution studies of two constructs of LXY1 imaging probes were also conducted.
Materials and methods
Materials Rink amide MBHA resin (0.5 mmol/g), Fmocprotected amino acids, and N-hydroxybenzotriazole (HOBt) were purchased from GL Biochem (Shanghai, China). 1,3-Diisopropylcarbodiimide (DIC) was purchased from Advanced ChemTech (Louisville, KY, USA). TentaGel S NH 2 resin (0.24 mmol/g, 1% DVB cross-linked 90 μm) was purchased from Rapp Polymere (Tubingen, Germany). The other chemical reagents were purchased from Aldrich (Milwaukee, WI, USA) and were of analytical grade. Anti-α3 and anti-β1 integrin antibodies were purchased from Chemicon International. Human glioblastoma cell line U-87MG was obtained from American Type Culture Collection (Manassas, VA, USA) and was maintained at 37°C in a humidified atmosphere containing 5% CO 2 in Eagle's minimum essential medium and 10% fetal bovine serum (Omega Scientific).
Synthesis of the cyclic peptide cdGLGBNc (LXY1) on TentaGel resins for on-bead cell binding assay Fmoc chemistry and HOBt/DIC coupling [8] was used to synthesize the cyclic peptide on beads. Threefold molar excess of Fmoc-protected amino acids to resin were used for coupling. The reaction was monitored with the ninhydrin test. The Fmoc group was deprotected with 20% piperidine in dimethylformamide. After the side chainprotecting groups were removed with trifluoroacetic acid (TFA) cocktail containing 82.5% TFA:5% phenol:5% thioanisole:5% H 2 O:2.5% triisopropylsilane, the peptide on beads were cyclized in 20% dimethyl sulfoxide (v/v) for 48 h. Cyclization completion was confirmed by the Ellman test. The beads were then washed with water and stored in 75% ethanol (v/v).
Synthesis of LXY1 and biotinylated cyclic peptide cdGLGBNc (LXY1) in soluble form LXY1 and biotinylated LXY1 (Fig. 1a) were synthesized on Rink resin (loading 0.5 mmol/g) using the above-described Fmoc chemistry [8] . cdGLGBNc-linker-linker-biotin was prepared on Rink resin using Fmoc-Lys(Alloc) as the first building block. After Alloc deprotection, biotin was coupled to amino group at the ɛ position of Lys. Fmoc-linker [9] and Fmocamino acids were coupled to resin sequentially, followed by Fmoc deprotection. The peptides were finally cleaved from the Rink resins using the TFA cocktail and then precipitated in cold diethyl ether. The crude peptides were cyclized in 50 mM NH 4 HCO 3 buffer [10] and then purified by preparative reverse-phase high-performance liquid chromatography (RP-HPLC). Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) was employed to verify the identity of the cyclic peptides.
Synthesis of LXY1-Cy5.5 Fmoc-cdGLGBNc-linker-linkerLys(NH 2 )-CONH 2 was first constructed on Rink resin using Fmoc chemistry [8] . Then the compound was cleaved off the beads using the TFA cocktail solution to give linear FmoccdGLGBNc-linker-linker-Lys(NH 2 )-CONH 2 and precipitated with diethyl ether. The crude peptide was added to 50 mM NH 4 HCO 3 followed by the addition of charcoal. The mixture was stirred until the Ellman test was negative which indicated the completion of disulfide formation. After filtration, the solution was lyophilized and purified by preparative RP-HPLC. To the cyclic peptide FmoccdGLGBNc-linker-linker-Lys(NH 2 )-CONH 2 in 0.1 M NaHCO 3 (pH 8.3), Cy5.5-NHS was added. The mixture was mixed gently in the dark overnight, followed by Fmoc deprotection with 20% piperidine. The final product (Fig. 1b) was purified by preparative RP-HPLC and verified by MALDI-TOF MS.
The whole-cell binding assay U-87MG cells adherent to the bottom of the T75 flask were trypsinized with 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA) and neutralized with growth medium. Floating cells were collected, spun down, and resuspended with 10 mL growth medium in a 10-cm Petri dish. Then LXY1 beads were washed sequentially with ethanol, water, and phosphate-buffered saline (PBS). Thereafter, the beads were incubated with suspended U-87MG cells and the whole dish was kept shaking at a speed of 40 rpm inside an incubator at 37°C under 5% CO 2 . The plate was then examined under an inverted microscope every 15 min.
Binding affinity of LXY1 peptide detected by flow cytometry U-87MG cells with 80-90% confluence were dissociated with 0.05% trypsin-EDTA and neutralized with growth medium. Each sample with 3×10 5 cells was incubated with biotinylated LXY1 at different concentrations in 50 μL PBS containing 10% fetal bovine serum (FBS) and 1 mM MnCl 2 for 30 min on ice. To determine nonspecific binding, the samples were incubated with 10 μg anti-α3 integrin antibody for 30 min prior to incubation with biotinylated LXY1. After peptide incubation, each sample was washed three times with 1 mL PBS containing 1% FBS. Samples were incubated with 1:500 dilution of streptavidin-PE (1 mg/mL) for 30 min on ice followed by washing once with 1 mL PBS containing 1% FBS. Finally, the samples were analyzed with flow cytometry (Coulter XL-MCL), and the mean fluorescence intensity (MFI) was determined. The apparent K d was calculated using the GraphPad Prism software (http:// www.graphpad.com).
Fluorescence microscopy Sample preparation was the same as above-described for flow cytometry studies. Instead of running the cells through a flow cytometer, the cells were examined under a fluorescent microscope. To conduct the blocking experiment, unlabeled LXY1 peptide and anti-α3 integrin antibody were incubated with the cells together with the biotinylated LXY1. After the last wash, the cell pellet was resuspended in 100 μL PBS and loaded into the container for Cytospin centrifuge (Cytospin3, Shandon). The cells were spun down onto slides at 2,000 rpm for 2 min and mounted by the fluorescence mount solution including DAPI. Thereafter, the cells were covered by cover slip and examined under a fluorescence microscope (IX81, Olympus).
Tumor xenografts Animal studies were performed according to a protocol approved by Institutional Animal Care and Use Committee of the University of California, Davis. Female athymic nude mice (nu/nu), obtained from Harlan (Indianapolis, IN) at 5-6 weeks of age, were injected subcutaneously in the right flank with 5×10 6 U-87MG glioblastoma cells suspended in 200 μL PBS. In some mice, 5×10 6 K562 chronic myeloid leukemia cells were implanted in the opposite side as a negative control. For the orthotopic implantation, 2.5×10 5 cells in 5 μL PBS were injected into the right striatum area of the mouse with the aid of a mouse stereotactic instrument (Stoelting). When the subcutaneous tumors reached 0.5 to 1.0 cm in diameter or 21-28 days after implantation, at that time the mean size of orthotopic tumors was 0.2 to 0.5 cm in diameter, the tumorbearing mice were subjected to in vivo and ex vivo imaging studies.
Near-infrared fluorescence imaging studies Tetravalent LXY1-biotin-streptavidin complex (1.8 nmol), prepared by mixing 7.2 nmol of biotinylated LXY1 with 1.8 nmol of streptavidin-Cy5.5 in PBS overnight at 4°C or 7.2 nmol of univalent LXY1-Cy5.5 conjugate, was injected via the tail vein in the mouse anesthetized by injection of 30 μL nembutal (50 mg/mL) before imaging. To conduct blocking experiments, 3.6 μmol of LXY1 or 20 μg anti-α3 integrin antibody was injected via tail vein 1 h prior to injection of the optical probe. Animals were placed on a sheet of transparency in the supine position. Images were acquired with a Kodak IS2000MM Image station (Rochester, NY, USA) with excitation filter 625/20 band pass, emission filter 700WA/35 band pass, and 150 W quartz halogen lamp light source set to maximum. Images were captured with a CCD camera set at F stop=0, FOV=150, and FP=0. Data were collected at different time points and analyzed using the Kodak ID 3.6 software by drawing the region of interest (ROI) on the imaged mouse. In ex vivo imaging, the mice were killed and organs excised for imaging.
Data processing and statistics For determination of tumor contrast, we calculated the MFIs of the tumor area and of the normal tissue area by means of the ROI function using the Kodak 1D Image Analysis Software (Kodak). All the data are shown as the mean±SD of n independent measurements. Student's t test was used for statistical analysis of ex vivo imaging intensity. Statistical significance was indicated by p<0.05 and p<0.001.
Results

LXY1 TentaGel beads binding with U-87MG cells LXY1
peptide was resynthesized on TentaGel beads. When U-87MG cells were incubated with the LXY1 beads, the beads were entirely covered by a monolayer of cells within 30 min (Fig. 2a) , indicating that the LXY1 peptide strongly binds to U-87MG cells.
Binding affinity of LXY1 against U-87MG Cells We used flow cytometry to determine the apparent binding affinity of the LXY1 peptide against U-87MG cells. U-87MG cells were treated with or without 10 μg anti-α3 integrin antibody for 30 min prior to incubation with biotinylated LXY1. After thorough washing, the cells were mixed with streptavidin-PE for 30 min, washed, and then analyzed by flow cytometry. The MFI of the group pretreated with antibody is depicted as the nonspecific binding of the peptide to the cells and that of the group treated with only peptides is defined as total binding. By subtracting nonspecific binding from total binding at various concentrations of the peptide, the apparent K d for the specific binding of LXY1 was calculated to be 0.5±0.1 μM (Fig. 2b) .
Fluorescent staining of U-87MG cells with LXY1 peptide The U-87MG cells were incubated with biotinylated LXY1 for 30 min, washed three times with PBS, incubated with streptavidin-Alexa488 for 30 min, washed once with PBS, and then examined under a fluorescent microscope. For the blocking experiments, unlabeled LXY1 peptide or anti-α3 antibody was added prior to the introduction of biotinylated LXY1. Figure 3a clearly demonstrates that cell staining by biotinylated LXY1 was almost completely abolished by either unlabeled LXY1 or anti-α3 antibody, indicating that LXY1 peptide binds specifically to the α3-integrin of U-87MG glioblastoma cells.
In vivo and ex vivo near-infrared optical imaging of subcutaneous and orthotopic U-87MG xenograft implant in nude mice To maintain the 4:1 molar ratio of biotin/ streptavidin, 7.2 nmol biotinylated LXY1 was mixed with 1.8 nmol of streptavidin-Cy5.5 (based on streptavidin) to form a tetravalent complex prior to injection into the mice via the tail vein. In the biodistribution study, ex vivo NIRF imaging was conducted at 30 min, 4 h, 6 h, 24 h, and 48 h after injection. The accumulation of the tetravalent optical probe in U-87MG tumor peaked at around 4 h and then decreased gradually, but with over 80% of the peak level retained in the tumor even at 48 h. Renal uptake of the tetravalent optical probe followed similar pharmacokinetics. NIRF probe uptake into the skin and liver was also seen but was significantly lower than that of the tumor and the kidneys (Fig. 6a) . To determine tumor-targeting specificity, U-87MG cells were implanted subcutaneously to one side of the nude mouse. K562 chronic myeloid leukemia cells (expressing α5β1 integrin) were injected into the opposite side of the same nude mouse as a negative control. After the tumors reached 0.5 to 1.0 cm in diameter, the mice bearing both U-87MG and K562 tumors were injected via tail vein with 1.8 nmol of the tetravalent LXY1-biotin-SA-Cy5.5 complex. Four hours postinjection, the animals were scanned with the Kodak Imaging Station. Figure 3b clearly shows that the uptake of the NIRF probe into the U-87MG tumor was statistically significantly higher than that of K562.
For the in vivo blocking experiments, 3.6 μmol unlabeled LXY1 peptide or 20 μg (approximately 0.13 nmol) anti-α3 integrin antibody was administered intravenously 1 h prior to the administration of the tetravalent complex. Ex vivo organs and tumor imaging studies (Fig. 4a, b) clearly demonstrate that uptake of the NIRF probe by the U-87MG tumor was much higher than that of the K562 tumor (p< 0.001). Furthermore, uptake of the imaging probe by the U-87MG tumor was almost completely blocked by prior injection with either excess unlabeled LXY1 (p<0.001) or anti-α3 integrin antibody (p<0.001). These results further demonstrate that LXY1 is highly specific against the α3 integrin receptor on the U-87MG tumor. Kidney uptake of the NIRF probe was significant in these studies and was not blocked by unlabeled LXY1 nor anti-α3 integrin antibody. This is not unexpected as it has been reported in the literature that streptavidin alone does bind to kidney when administered intravenously. Uptake of the optical probe in other normal organs was moderate in the skin and liver but very low in other organs.
We have also performed NIRF imaging experiments in nude mice bearing both subcutaneous and orthotopic U-87MG implants. Ex vivo imaging studies shown in Fig. 5a and b clearly demonstrate that uptake of the NIRF probe into the subcutaneous tumor implant was very high while uptake into the normal organs was relatively low with the exception of the kidneys. Very importantly, uptake of the imaging probe by the orthotopic U-87MG implant in the right brain was also 
Þwhere K d is the apparent dissociation constant of the ligand much higher than that of the normal brain tissue (p<0.001), although it was lower than that of the subcutaneous U-87MG tumor (p<0.05).
We have also conducted in vivo imaging studies in nude mice bearing the U-87MG tumor with the much smaller univalent LXY1-Cy5.5 conjugate; 7.2 nmol of LXY1-Cy5.5 was injected via tail vein and ex vivo imaging was conducted at 15 min, 1 h, 2 h, 4 h, and 24 h postinjection. Figure 6b shows that near-infrared signal in both the tumor and kidneys peaked within 15 min after intravenous injection of the optical probe, followed by a rapid clearance to approximately 50% of the peak level by 2 h, and then a much slower clearing phase over the next 22 h. This biodistribution result is very different from that obtained by the larger tetravalent conjugate in which tumor and kidney uptake peaked at 4 h followed by a very slow drop over the next 44 h (Fig. 6a) .
Discussion
The OBOC combinatorial library method was developed over a decade ago [11] . Thousands to millions of compound beads can be generated and screened rapidly. Each OBOC library compound bead displays only one chemical entity. One major advantage of the OBOC method over the phage display method is that D-amino acids, unnatural amino acids, and organic moieties can be easily incorporated into the construction of the OBOC libraries, rendering the identified ligands containing such building blocks more resistant to proteolysis. The phage display peptide library method, on the other hand, is generally limited to only Lamino acids, and therefore, the peptides are more susceptible to proteolysis [12] . Using OBOC combinational approaches, we have previously reported the identification of peptide and peptidomimetic ligands against cell surface receptors on several tumor types, such as α6β1 integrin of prostate cancer [13] , α4β1 integrin of malignant lymphoma [14, 15] , α3β1 integrin of nonsmall cell lung cancer [16] , and ovarian cancer [7] . The cD/NGXGXXc peptide motifs that we previously identified were found to bind α3β1 integrin of lung and ovarian cancers [7, 16] . Based on these results, a focused library cXGXGXXc was synthesized and screened against ovarian cancer cell lines [7] . Cyclic peptide OA02 or cdG-homocitrulline (Hci)-GPQc was developed and demonstrated to have good in vivo targeting properties both in optical [17] and PET imaging [12] of ovarian cancer xenografts. α3β1 integrin is expressed widely in normal organs and tumor tissues. It plays an important role in normal lung, kidney, and epithelial development, as well as neuronal migration during cerebral cortical development [18] [19] [20] [21] . It also plays a crucial role in tumor cell adhesion, migration, invasion, and metastasis [22] [23] [24] [25] . Many different kinds of epithelial tumors such as ovarian cancer, melanoma, and glioblastoma overexpress α3β1 integrin. Through screening focused OBOC libraries and retesting the positive ligands against a series of α3β1 integrin-expressing tumor cells, we noticed that the binding profile of these ligands against the different cell lines varies somewhat despite the ligands having the same cdGXGXXc motif [12] . We believe all these ligands do bind to α3 integrin because cell binding to such beads can be blocked by anti-α3 antibody. Our hypothesis is that the α3 integrins expressed on each of these cancer cell lines may have somewhat different conformation or states and are, therefore, different from α3 integrins expressed on normal cells. The hypothesis is supported by (1) our observation that LLP2A, the high-affinity and high-specificity peptidomimetic ligand against B and T lymphoma cells, binds strongly to the activated α4β1 integrin on these malignant cells, moderately to α4β1 integrin of normal peripheral blood mononuclear cells activated by Mn 2+ , but not to unactivated α4β1 integrin present on the resting lymphoid cells isolated from normal peripheral blood [14] and (2) the ex vivo imaging data (Fig. 4a) shows excellent uptake in subcutaneous tumor implant but much lower in many normal organs which also express α3 integrin.
We screened the focused cXGXGXXc library against glioblastoma cell line (U-87MG) and identified LXY1, which was found to bind to U-87MG cells at a moderately high affinity and with high specificity to the α3 integrin receptor on the cell surface. Unlike the anti-α3 integrin antibody, the anti-β1 integrin antibody was not able to block the binding of U-87MG cells to the LXY1 bead. A negative result, however, cannot rule out that β1 is not involved in the binding of LXY1 to U-87MG cells. Although optical imaging may not be useful as a noninvasive imaging agent for clinical glioblastoma, it is extremely useful as a preclinical imaging tool to evaluate or screen tumor-targeting ligands. Optical imaging is technically easy to do, nonradioactive, and relatively inexpensive. We can, therefore, use this approach to determine the cancer-targeting potential of a number of ligands; and based on the optical imaging result, we can then select a few ligands for further development into in vivo radiotargeting and chemotargeting agents. In this report, we first used the larger tetravalent LXY1-biotin-SA-Cy5.5 complex (approximately 64 kDa) as the NIRF optical imaging probe in a xenograft model. Uptake of the conjugate into the subcutaneous tumor implant was very high, as were the kidneys. High renal uptake of the conjugate is not unexpected as streptavidin is known to bind to the kidney [26] . Uptake of the conjugate to other normal organs, however, was very low (Fig. 6a) . For brain cancer-targeting agents, we need to demonstrate that these compounds can be effectively delivered to the tumors within the brain. To achieve this, we performed NIRF optical imaging studies in nude mice that have received both subcutaneous and orthotopic U-87MG implants. As expected, uptake of LXY1-biotin-streptavidin-Cy5.5 conjugate into the subcutaneous implant was very high and uptake into the kidneys was moderately high. More importantly, LXY1 uptake into the orthotopic implant was also very significant (Fig. 5a, b) . This observation, however, does not necessarily mean that the LXY1-biotin-streptavidin-Cy5.5 conjugate could penetrate the blood-brain barrier. More than likely, the bloodbrain barrier was compromised at the tumor site [27] and, therefore, allowed the LXY1 conjugate to reach the orthotopic target xenograft.
In addition to testing the large tetravalent LXY1-biotin-SA-Cy5.5 complex as an imaging probe, we also evaluated the tumor-targeting capability of the much smaller univalent LXY1-Cy5.5 conjugate (2,279 Da). The biodistribution studies showed that LXY1-Cy5.5 uptake in the subcutaneous U-87MG tumor peaked within 15 min after intravenous injection and was washed out quickly (within 4 h). The pharmacokinetic profile of this small conjugate was very different from that of LXY1-biotin-SA-Cy5.5 in which the uptake of the larger probe peaked at around 4 h with very slow wash out even after 48 h. This can, in part, be explained by the difference in size and valency of the conjugates. The prolonged retention of the streptavidin complex in the kidney is probably due to the nonspecific binding of streptavidin to the kidney [26] . Whether LXY1 Quantitative analysis of NIRF uptake is shown in b. NIRF signal in OT was significantly higher than that in normal brain tissue (n=3, p< 0.001) but lower than that in ST (n=3, p<0.001). Kidney uptake was as high as tumor uptake and liver uptake was significant directly binds to the kidney or not is unclear at this time as Cy5.5 itself may also bind to the kidneys. Preliminary data in our laboratory showed that LLP2A, the lymphomatargeting ligand, when conjugated to the metal chelator CB-TE2A and complexed with 64 Cu can obviate renal uptake (data not shown), suggesting that LLP2A does not bind to the renal cells even though LLP2A-biotin-SA-Alexa680 complex does [14] . We plan to synthesize LXY1-CB-TE2A conjugate and label it with 64 Cu for PET imaging studies. This study will enable us to determine if LXY1 binds to the kidney or not. It will also allow more precise biodistribution studies and clarify brain uptake levels of the new tracer in functional and impaired blood-brain barrier.
Eventually, direct conjugation of LXY1 with radionuclides without streptavidin will be developed. The smaller univalent conjugation may be more suitable to be used as the image radiotracer because of its quicker washout and shorter retention time. However, the multivalent conjugation with longer retention time but with lower kidney uptake will be the future direction for conjugation optimization. This can be accomplished by using branched polyethylene glycol instead of streptavidin as the scaffold for LXY1 conjugation. Should the 64 Cu-labeled LXY1-CB-TE2A conjugate target orthotopic and subcutaneous glioblastoma with high efficiency and specificity and with low uptake to the liver or kidney, the same ligand-metal chelate can be loaded with 6 a Biodistribution of the larger tetravalent LXY1-biotin-SA-Cy5.5 complex after injection into mice (n=3) bearing subcutaneous U-87MG tumor. NIRF ex vivo imaging was conducted at 30 min, 4 h, 6 h, 24 h, and 48 h after injection of LXY1-biotin-SA-Cy5.5 (n=3 for each time point). NIRF signal in U-87MG tumor and kidneys peaked at around 4 h after injection and majority of the signal remained even after 48 h. NIRF uptake into the liver and skin are significant. b Biodistribution of the smaller univalent LXY1-Cy5.5 conjugate injected into mice (n=3) bearing subcutaneous U-87MG tumor. NIRF ex vivo imaging were conducted at 15 min, 1 h, 2 h, 4 h, and 24 h after injection of LXY1-Cy5. 5 . NIRF signals in the tumor and kidneys peaked at 15 min followed by a rapid clearance within the first 4 h and then a slow washout with significant retention of the NIRF probe in these two sites even after 24 h. Liver and skin uptake was significant but the probe was cleared from these organs after 24 h cancer radiotherapy. If kidney uptake remains high with the small univalent radioconjugate, we shall prepare larger univalent or tetravalent radioconjugates by ligating LXY1 and CB-TE2A to an inert multibranched polyethylene glycol platform (50,000 Da) that is excluded from filtration through the glomeruli in the kidneys. An alternative route of administration of the radioconjugate is intralesional injection.
In summary, we have demonstrated that the LXY1 cyclic peptide, discovered through OBOC combinatorial library methods, can bind U-87MG brain tumor cells with high specificity and moderately high affinity. We have further shown that LXY1 can target both subcutaneous and orthotopic U-87MG implants with high specificity. We have also established the difference in the biodistribution profiles of LXY1-biotin-SA-Cy5.5 and LXY1-Cy5.5. Work is currently underway in our laboratory to develop LXY1 into an effective vehicle for the delivery of radiotherapeutic and chemotherapeutic drugs to the glioblastoma.
